ShareValue scores for BJDX: Valuation 64, Quality 43, Growth 41, Health 52.

Bluejay Diagnostics Inc logo

BJDX
NASDAQ

Bluejay Diagnostics Inc

$1.15(-7.26%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 17%
Valuation
64
Fair Value
Price vs Value
Quality
43
Moderate
Business Strength
Growth
41
Moderate
Revenue & Earnings
Health
52
Moderate
Financial Stability
Momentum
19
Bearish
Price Trend

Company Details

About

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026